Sign up for our FREE Orthopedic E-Weekly for more coverage like this sent to your inbox!
Alphatec Holdings’ Alphatec Spine reported $47.6 million in 3Q revenue, a 6.2 percent increase over the same period last year. The company’s revenue growth was driven by the U.S. market, reporting an increase of 8.9 percent. The company re-launched Alphatec Solus during 3Q and introduced three new products.
ArthroCare reported $83.3 million during 3Q, a 3.7 percent decrease from the same period last year. The company’s worldwide sports medicine sales experienced a 1.6 percent increase, which wasn’t enough to off set poor overall sales in the U.S. Market.
Biomet experienced a 4 percent increase in net sales during 2Q of the 2012 fiscal year, despite a 5 percent drop in worldwide spine sales. This comes after a 10 percent drop in spine sales during 1Q of FY 2012. The company reported worldwide net sales of $725 million in 2Q, while U.S. net sales increased by 2 percent.
Johnson & Johnson’s DePuy Orthopaedics reported a 1.5 percent decrease in U.S. sales during the third quarter of 2011. Worldwide sales increased by 5.7 percent. Johnson & Johnson reported $109 million in total expenses due to litigation matters related to the recall of the DePuy ASR Hip implant in the summer of 2010.
Plainsboro, N.J.-based Integra LifeSciences reported $202 million in total 3Q revenues, an 8 percent increase over 3Q of 2010. The company’s success was driven by the acquisition of Ascension Orthopedics, and the orthopedics product sales, which grew by 18 percent. Its neurosurgery business grew by 4 percent during 3Q.
InVivo Therapeutics, a company focused on finding solutions for spinal cord injury, reported 3Q net income of $3 million. During the third quarter, the company submitted an IDE and plans to begin human clinical study with the its proprietary biopolymer scaffolding device for acute spinal cord injury, pending FDA approval.
Exton, Pa.-based Kensey Nash reported an 18 percent increase in 3Q revenue to $20 million and 29 percent increase in net sales to $14 million. The company’s success was driven by a 113 percent increase in its spine business, due to the acquisition of Norian from Synthes. Its sports medicine business also grew by 36 percent, and total orthopedic sales were up by 140 percent.
Robotic orthopedic device company Mako Surgical reported 3Q revenue of $20 million, a 67 percent increase over the same period in 2010. The company reported selling 11 RIO systems and supporting 1,813 MAKOplasty procedures during 3Q. The company also launched its total hip arthroplasty application during this time, which sold 12 applications during the quarter.
Spine device company Mazor Robotics reported $1.6 million in 3Q sales, which is a slight increase over the same period last year. During 3Q, the company sold three of its Renaissance systems for robotic guidance during spinal surgery.
Medtronic reported 2Q revenue of $4.1 billion, which is a 6 percent increase over the same period last year. The company’s success was driven by international revenue, which offset a 1 percent decrease in spinal revenue. Medtronic’s spinal business reported a 4 percent decrease in biologics due to poor sales of Infuse.
Spine device company NuVasive reported 3Q revenue of $132.9 million, which was a 10.5 percent increase over the same period last year. Company CEO Alex Lukianov attributed its success to transactions that enhanced its penetration into the lateral lumbar interbody fusion and NeuroVision markets.
Orthofix reported 3Q net sales of $144.7 million, representing a 4 percent increase over 3Q of 2010. The company suffered a 31 percent decrease in divested products and 1 percent decrease in spinal products. However, its orthopedics and sports medicine businesses experienced a 16 and 8 percent increase over last year, respectively.
RTI Biologics reported worldwide 3Q revenues of $42.3 million, a 1 percent increase over the same period last year. The company’s quarterly domestic revenue was comparable to the figure reported in 2010. The company attributed its success to growth in its surgical specialties and bone graft substitute/general orthopedic implants business.
Alpharetta, Ga.-based medical device company Sanuwave Health reported a 42 percent decrease in revenue for 3Q of 2011. The company introduced orthoPACE to the European market during 3Q, which incurred a one-time charge associated with sales of demonstration for the device.
Revenue was up for Smith & Nephew during 3Q, despite poor market growth from its orthopedics business. The company’s overall revenue increased by 10 percent to $1 billion over the same period last year, but orthopedics sales only increased by 3 percent to $548 billion. As a result, CEO Olivier Bohuon said the company would take steps to reduce the cost base in orthopedics.
Stryker‘s net sales showed a 14.9 percent increase during 3Q. The company reported $2 billion in net sales, but net earnings decreased by 3 percent. The company’s reconstructive products reported 8 percent increase in sales, driven by acquisitions of Orthovita and Memomental earlier this year. The company’s spine business grew by 121 percent to $184 million, offsetting low growth by its hip and knee businesses.
For the first time, Synthes‘ quarterly revenue exceeded $1 billion, an 11 percent increase over last year. The company’s success was driven by double-digit growth in the international markets and new product launches in the European market. Net sales in the North American market experienced a 5 percent growth, compared to 17.3 percent and nearly 30 percent in the European and Asian Pacific markets. The company’s shareholders recently approved an acquisition bid from Johnson & Johnson.
The global extremities business drove Tornier‘s 3Q 16 percent sales growth. The company reported $57.6 million in total sales, with a 15 percent increase in overall extremities sales. The company underperformed in U.S. markets for lower extremities, sports medicine and biologics.
Wright Medical Group reported a 3 percent decrease in net sales during 3Q to $118.2 million. Domestic sales decreased by 7 percent while international sales only grew by 3.6 percent. Knee, hip and biologics sales decreased for the company, while extremities sales grew by 7.5 percent.
Overseas markets drove Zimmer‘s 6.9 percent sales increase during 3Q. The company reported net sales of $1 million, due to a 17 percent increase in the European market and 19 percent increase in the Asian Pacific market. Sales in the American market remained flat.
Related Articles on Orthopedic Devices:
Exactech Begins Trial for Cartilage Repair Technology
39 Orthopedic & Spine Devices Receive FDA 510(k) Clearance in November
MedShape Receives Patent for Memory Technology
